EGFR and non-small cell lung carcinoma: The FLAURA study, a phase III trial, showed that osimertinib substantially prolonged PFS and improved response in patients with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression to prior EGFR-TKI treatment.